ADRs (Adverse Drug Reactions) related to ayurvedic medicine used in COVID-19

IF 0.8 Q3 MEDICINE, GENERAL & INTERNAL

Bangladesh Journal of Medical Science Pub Date : 2024-01-01 DOI:10.3329/bjms.v23i1.70756

M. Kumari, A. Ramamurthy, Sudipta Rath, Syed Ziaur Rahman

{"title":"ADRs (Adverse Drug Reactions) related to ayurvedic medicine used in COVID-19","authors":"M. Kumari, A. Ramamurthy, Sudipta Rath, Syed Ziaur Rahman","doi":"10.3329/bjms.v23i1.70756","DOIUrl":null,"url":null,"abstract":"Background: Adverse Drug Reaction (ADR) is a response to a drug which is noxious and unintended, and which occurs at therapeutic doses. Due to a lack of systematic documentation regarding the occurrence of ADR and other issues to the safety of Ayurvedic medicines, concern about the traditional medical system has recently been increased. This is seen by a rise in safety reports and misunderstandings, especially in the recent pandemic. \nObjective: To monitor and analyse the suspected ADR to Ayurvedic medicines used in COVID-19. \nMaterials and Methods: ADR monitoring data was collected through spontaneous and intensive method for a span of 2-year (April 2020 to April 2022) during the peak days of COVID-19 from the IPvCC of the National Institute of Ayurveda, Jaipur, India. The IPvCC Program is governed by NPvCC under the supervision of Ministry of AYUSH, Govt. of India, New Delhi. NPvCC is ultimately responsible to monitor and recommend regulatory interventions on the generated national ADR data. \nResult: In a span of two-year, 142 adverse drug events were reported out of which 17 were confirmed as ADR due to suspected Ayurvedic drugs. \nConclusion: Overall review demonstrated that Ayurveda has traditionally been placed a strong emphasis on treatments that aim to heal the underlying illness while preventing the development of new illnesses. \nBangladesh Journal of Medical Science Vol. 23 No. 01 January’24 Page : 237-245","PeriodicalId":8696,"journal":{"name":"Bangladesh Journal of Medical Science","volume":"24 11","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bangladesh Journal of Medical Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3329/bjms.v23i1.70756","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Adverse Drug Reaction (ADR) is a response to a drug which is noxious and unintended, and which occurs at therapeutic doses. Due to a lack of systematic documentation regarding the occurrence of ADR and other issues to the safety of Ayurvedic medicines, concern about the traditional medical system has recently been increased. This is seen by a rise in safety reports and misunderstandings, especially in the recent pandemic. Objective: To monitor and analyse the suspected ADR to Ayurvedic medicines used in COVID-19. Materials and Methods: ADR monitoring data was collected through spontaneous and intensive method for a span of 2-year (April 2020 to April 2022) during the peak days of COVID-19 from the IPvCC of the National Institute of Ayurveda, Jaipur, India. The IPvCC Program is governed by NPvCC under the supervision of Ministry of AYUSH, Govt. of India, New Delhi. NPvCC is ultimately responsible to monitor and recommend regulatory interventions on the generated national ADR data. Result: In a span of two-year, 142 adverse drug events were reported out of which 17 were confirmed as ADR due to suspected Ayurvedic drugs. Conclusion: Overall review demonstrated that Ayurveda has traditionally been placed a strong emphasis on treatments that aim to heal the underlying illness while preventing the development of new illnesses. Bangladesh Journal of Medical Science Vol. 23 No. 01 January’24 Page : 237-245

查看原文本刊更多论文

与 COVID-19 中使用的阿育吠陀药相关的 ADR（药物不良反应

背景：药物不良反应（ADR）是指在治疗剂量下出现的一种有害的、非预期的药物反应。由于缺乏关于药物不良反应发生情况的系统记录，以及阿育吠陀药物安全性方面的其他问题，人们最近对传统医学体系的关注有所增加。这从安全报告和误解的增加可以看出，尤其是在最近的大流行病中。目标：监测和分析 COVID-19 中使用的阿育吠陀药物的可疑 ADR。材料与方法：在 COVID-19 高峰期的两年内（2020 年 4 月至 2022 年 4 月），通过自发和密集的方法从印度斋浦尔国家阿育吠陀研究所的 IPvCC 收集 ADR 监测数据。IPvCC 计划由新德里印度政府阿育吠陀部监督下的 NPvCC 管理。NPvCC 最终负责对生成的国家 ADR 数据进行监测并提出监管干预建议。结果：在两年的时间里，共报告了 142 起药物不良反应事件，其中 17 起被证实为疑似阿育吠陀药物引起的药物不良反应。结论总体回顾表明，阿育吠陀历来重视治疗，旨在治愈潜在疾病的同时预防新疾病的发生。孟加拉国医学科学杂志》第 23 卷第 01 期 January'24 Page : 237-245

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊